138 related articles for article (PubMed ID: 25694511)
1. Highly specific role of the insulin receptor in breast cancer progression.
Rostoker R; Abelson S; Bitton-Worms K; Genkin I; Ben-Shmuel S; Dakwar M; Orr ZS; Caspi A; Tzukerman M; LeRoith D
Endocr Relat Cancer; 2015 Apr; 22(2):145-57. PubMed ID: 25694511
[TBL] [Abstract][Full Text] [Related]
2. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.
Ferguson RD; Novosyadlyy R; Fierz Y; Alikhani N; Sun H; Yakar S; Leroith D
Breast Cancer Res; 2012 Jan; 14(1):R8. PubMed ID: 22226054
[TBL] [Abstract][Full Text] [Related]
3. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
Kim JG; Kang MJ; Yoon YK; Kim HP; Park J; Song SH; Han SW; Park JW; Kang GH; Kang KW; Oh DY; Im SA; Bang YJ; Yi EC; Kim TY
PLoS One; 2012; 7(3):e33322. PubMed ID: 22438913
[TBL] [Abstract][Full Text] [Related]
4. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
Erdem C; Lee AV; Taylor DL; Lezon TR
PLoS Comput Biol; 2021 Jun; 17(6):e1009125. PubMed ID: 34191793
[TBL] [Abstract][Full Text] [Related]
6. Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells.
Vella V; Giuliano M; La Ferlita A; Pellegrino M; Gaudenzi G; Alaimo S; Massimino M; Pulvirenti A; Dicitore A; Vigneri P; Vitale G; Malaguarnera R; Morrione A; Sims AH; Ferro A; Maggiolini M; Lappano R; De Francesco EM; Belfiore A
Cells; 2021 Nov; 10(11):. PubMed ID: 34831367
[TBL] [Abstract][Full Text] [Related]
7. High levels of dietary soy decrease mammary tumor latency and increase incidence in MTB-IGFIR transgenic mice.
Watson KL; Stalker L; Jones RA; Moorehead RA
BMC Cancer; 2015 Feb; 15():37. PubMed ID: 25655427
[TBL] [Abstract][Full Text] [Related]
8. IGF1 and Insulin Receptor Single Nucleotide Variants Associated with Response in HER2-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without a Fasting Mimicking Diet (BOOG 2013-04 DIRECT Trial).
de Gruil N; Böhringer S; de Groot S; Pijl H; Kroep JR; Swen JJ
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136416
[TBL] [Abstract][Full Text] [Related]
9. Behavioral Characterizing of CD24 Knockout Mouse-Cognitive and Emotional Alternations.
Nitzan K; Toledano R; Shapira S; Arber N; Doron R
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33562144
[TBL] [Abstract][Full Text] [Related]
10. Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies.
Salisbury TB; Tomblin JK
Front Endocrinol (Lausanne); 2015; 6():12. PubMed ID: 25699021
[TBL] [Abstract][Full Text] [Related]
11. CD24(+) cells fuel rapid tumor growth and display high metastatic capacity.
Rostoker R; Abelson S; Genkin I; Ben-Shmuel S; Sachidanandam R; Scheinman EJ; Bitton-Worms K; Orr ZS; Caspi A; Tzukerman M; LeRoith D
Breast Cancer Res; 2015 Jun; 17(1):78. PubMed ID: 26040280
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Syndrome, Type 2 Diabetes, and Cancer: Epidemiology and Potential Mechanisms.
Ben-Shmuel S; Rostoker R; Scheinman EJ; LeRoith D
Handb Exp Pharmacol; 2016; 233():355-72. PubMed ID: 25903410
[TBL] [Abstract][Full Text] [Related]
13. The role of the insulin-like growth factor-1 system in breast cancer.
Christopoulos PF; Msaouel P; Koutsilieris M
Mol Cancer; 2015 Feb; 14():43. PubMed ID: 25743390
[TBL] [Abstract][Full Text] [Related]
14. Insulin priming effect on estradiol-induced breast cancer metabolism and growth.
Wairagu PM; Phan AN; Kim MK; Han J; Kim HW; Choi JW; Kim KW; Cha SK; Park KH; Jeong Y
Cancer Biol Ther; 2015; 16(3):484-92. PubMed ID: 25701261
[TBL] [Abstract][Full Text] [Related]
15. Proliferative and signaling activities of insulin analogues in endometrial cancer cells.
Aizen D; Sarfstein R; Bruchim I; Weinstein D; Laron Z; Werner H
Mol Cell Endocrinol; 2015 May; 406():27-39. PubMed ID: 25697343
[TBL] [Abstract][Full Text] [Related]
16. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
17. Insulin Receptor Isoforms in Physiology and Disease: An Updated View.
Belfiore A; Malaguarnera R; Vella V; Lawrence MC; Sciacca L; Frasca F; Morrione A; Vigneri R
Endocr Rev; 2017 Oct; 38(5):379-431. PubMed ID: 28973479
[TBL] [Abstract][Full Text] [Related]
18. Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells.
Stella S; Massimino M; Manzella L; Parrinello NL; Vitale SR; Martorana F; Vigneri P
Front Endocrinol (Lausanne); 2023; 14():1081831. PubMed ID: 37361518
[TBL] [Abstract][Full Text] [Related]
19. The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities.
Ennis CS; Llevenes P; Qiu Y; Dries R; Denis GV
Front Endocrinol (Lausanne); 2022; 13():1044670. PubMed ID: 36531496
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
